Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax Inc (NASDAQ: NVAX) delayed ramping up COVID-19 vaccine production again on Monday and said it was unlikely to seek regulatory approval for its shot in Europe, UK, and the United States until Q3 of 2021. Shares of the company slid about 7% in premarket trading on Tuesday.

Here's why Novavax stock fell again on Tuesday morning

Moderna

The Covid-19 treatment response process includes a number of different major players, including Pfizer Inc (NYSE: PFE), BioNTech SE – ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA), AstraZeneca plc (NASDAQ: AZN), Novavax Inc (NASDAQ: NVAX), Halberd Corp (OTC US: HALB), and Johnson & Johnson (NYSE: JNJ). The pandemic is under control.

New Approaches to Covid-19 Treatment Enter the Picture

Vaccine stocks had a rough week, with Novavax stock down almost -25%, Moderna down by about -9%, and Pfizer stock up by just about 2% despite posting a very solid set of first-quarter results. The decline is largely driven by the Biden administration's support of the temporary waiver of.

Moderna And Novavax Stocks Fall On IP Waiver Concerns, But Sell Off Is Overdone

AstraZeneca

BioNTech SE

Johnson & Johnson

Pfizer

The government is having issues with giving away its excess supply.

How Will the U.S. Glut of Coronavirus Vaccines Affect Manufacturers?

It had nothing to do with the company's financial performance.

Here's the Only Thing in Novavax's Q1 Update That Investors Cared About

Novavax Inc. has delayed plans to seek regulatory clearances for its COVID-19 vaccine, while shortages in raw materials are slowing the ramp-up of production of doses, the company said.

The Wall Street Journal: Novavax delays its COVID-19 vaccine timeline

Novavax (NVAX) delivered earnings and revenue surprises of -15.09% and 53.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Reports Q1 Loss, Tops Revenue Estimates

The company's latest coronavirus vaccine news produced an unpleasant side effect.

Why Novavax Tanked Monday

Novavax Inc said on Monday it will ramp up production of its COVID-19 vaccine slower than it had previously anticipated and does not expect to file for regulatory approval in the United States, Britain or Europe until the third quarter of 2021.

Novavax again delays COVID-19 vaccine production timeline, shares fall

Shares of Novavax (NASDAQ:NVAX) rose after the company reported Q1 results. Quarterly Results Earnings per share were down 425.86% over the past year to ($3.05), which beat the estimate of ($3.60).

Novavax: Q1 Earnings Insights

GAITHERSBURG, Md., May 10, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the first quarter ended March 31, 2021.

Novavax Reports First Quarter 2021 Financial Results and Operational Highlights

Amazon

GameStop

MicroStrategy Incorporated

Silvergate Capital Corp

Tesla

A big capital gains tax is looming, threatening to trigger a selloff on companies whose stock ran up the most. The post 7 Stocks Most at Risk of a Capital Gains Tax Selloff  appeared first on InvestorPlace.

7 Stocks Most at Risk of a Capital Gains Tax Selloff

Novavax, Inc. (NVAX) announced positive results from the animal study of its combo vaccine for influenza and COVID-19. The positive news however did little to stem the sell-off in shares that began in late April.

Why Novavax Shares Down, Despite Positive Results from Flu/COVID-19 Vaccine Testing

Novavax (NASDAQ: NVAX) shares are trading lower amid reports competing COVID-19 vaccines may be approved in Europe. The stock also dipped on reports the company is unlikely to seek emergency use authorization for its COVID-19 vaccine until June.

Why Novavax Shares Are Trading Lower Today

NVAX reports earnings Monday after-hours. Do Q1 earnings really matter? NVAX bulls anticipate an EUA filing soon. If management does not expect EUA to occur soon then the stock could fall.

Novavax Faces Stormy Seas On Monday

- Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus - Data shared via preprint server for biology, bioRxiv, ahead of publication GAITHERSBURG, Md., May 10, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from a preclinical study of the company's combination quadrivalent seasonal flu vaccine (NanoFlu™) and COVID-19 vaccine candidate (NVX-CoV2373).

Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate

BeiGene

Galmed Pharmaceuticals

Sinovac Biotech

Shineco

The WHO approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the global pandemic. CoronaVac is the first China-developed COVID-19 vaccine under consideration in Europe, joining vaccines from CureVac, Novavax and a Russian vaccine, Sputnik V.

Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines

The Biden administration supports suspending COVID-19 vaccine IP rights.

COVID-19 Vaccine Makers Slump After U.S. Supports Suspending IP Rights

Should Novavax Be Worried About Losing IP Rights?

Pfizer fell Thursday by as much as 5% from Wednesday's close while Moderna dipped by almost 12% before both stocks recovered most of those losses.

Covid vaccine makers' shares seesaw after Biden administration says it will back patent waivers

Vaccine stocks — including BioNTech and Moderna stocks — pared deep losses Thursday after German Chancellor Angela Merkel said that she opposed waiving Covid vaccine patent rights. The post Vaccine Stocks Pare Deep Losses As Angela Merkel Opposes Waiving Patents appeared first on Investor's Business Daily.

Vaccine Stocks Pare Deep Losses As Angela Merkel Opposes Waiving Patents

uniQure

Moderna, Inc. (NASDAQ: MRNA). uniQure N.V.

Why Moderna, uniQure And Novavax Are Moving Today

Novavax to deliver 350 million doses beginning Q3 2021 1.1 billion doses of Novavax vaccine to be available to countries participating in COVAX Serum Institute of India to provide balance of doses for LMICs Underscores commitment to global equitable access to Novavax vaccine GAITHERSBURG, Md., May 6, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has finalized an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi) for supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility.

Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility

If enacted, such a move would hit the smaller vaccine makers particularly hard.

Biden Administration Supports Patent Waivers for Coronavirus Vaccine

GAITHERSBURG, Md., May 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from the initial primary analysis of a Phase 2b clinical trial conducted in South Africa of its NVX-CoV2373 COVID-19 vaccine candidate in the New England Journal of Medicine (NEJM).

New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant

News for Novavax Stock (NVAX)